Efficacy and tolerability of frovatriptan in clinical practice - Results of two surveys with 16 737 migraineurs;Wirksamkeit und verträglichkeit von frovatriptan in der praxis - Ergebnisse zweier anwendungsbeobachtungen mit 16 737 migränepatienten

Nervenheilkunde

Volumn 26, Issue 3, 2007, Pages 180-185

  Diener, Hans Christoph ^a   Pfaffenrath, V ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Neurologe   (Germany)

Author keywords

Efficacy; Frovatriptan; Migraine therapy; Onset of action; Prescription survey; Recurrence; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; FROVATRIPTAN; IBUPROFEN; PARACETAMOL;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ECONOMIC ASPECT; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE AURA; NAUSEA AND VOMITING; OUTPATIENT; PAIN ASSESSMENT; PHYSICIAN; POPULATION RESEARCH; RECURRENCE RISK; RECURRENT DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34347337527     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626847     Document Type: Article

References (11)

1. Diener H, Limmroth V, Fritsche G, Brune K, Kropp P, May A, Straube A, Evers S. Therapie der Migräneattacke und Migräneprophylaxe. Leitlinie der Deutschen Gesellschaft für Neurologie und der Deutschen Migräne- und Kopfschmerzgesellschaft. In: Diener H, für die Kommission Leitlinien der DGN (Eds.). Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Auflage. Stuttgart: Thieme 2005.
2. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75.
3. Oldman A, Smith L, McQuay H, Moore R. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002; 97: 247-57.
4. Visser WH, Jaspers N, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996 ;16 :264-9.
5. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 Suppl 1: S20-30.
6. Pascual J, Diener HC, Massiou H. Value of post-marketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. J Headache Pain 2006; 7: 27-33.
7. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 2004; 20: 1465-72.
8. 1B/1D receptor agonist for migraine. Int J Clin Pract 2004; 58: 695-705.
9. Goldstein J. Frovatriptan: a review. Expert Opin Pharmacother 2003; 4: 83-93.
10. Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005; 30: 521-32.
11. Pfaffenrath V, Spierings E. H. Akutbehandlung von Migräneattacken, Frovatriptan 2,5 mg als effektive und ökonomische Alternative. Nervenheilkunde 2004; 23: 545-9.